Get the Stockscreener App
4.27
0.70%
-0.03
Pre-market:
4.28
0.01
+0.23%
Humacyte Inc Stock (HUMA) Latest News
Humacyte, Inc. (HUMA) Laps the Stock Market: Here's Why - MSN
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: What You Should Know - MSN
Investing in Humacyte Inc (HUMA) Is Getting More Attractive - Knox Daily
Financial Analysis: Humacyte Inc (HUMA)’s Ratios Unveil Key Insights - The Dwinnex
Examining Humacyte Inc (HUMA) more closely is necessary - US Post News
Wealth Effects LLC Buys 57,200 Shares of Humacyte, Inc. (NASDAQ:HUMA) - MarketBeat
Humacyte (NASDAQ:HUMAW) Trading Down 1% – What’s Next? - Defense World
Why Is Bioengineered Human Tissue-Focused Humacyte Stock Surging On Friday? - AOL
Humacyte and Pluristyx enhance partnership for diabetes treatment By Investing.com - Investing.com South Africa
Humacyte, Pluristyx Announce Gene Editing Partnership -January 28, 2025 at 12:05 pm EST - Marketscreener.com
Humacyte and Pluristyx enhance partnership for diabetes treatment - Investing.com India
Humacyte and Pluristyx Announces Gene Editing Partnership to Support BioVascular Pancreas (BVP?) Development Using iPSCs - Marketscreener.com
Humacyte and Pluristyx Announce Gene Editing Partnership to Support BioVascular Pancreas (BVP™) Development Using iPSCs - The Manila Times
Revolutionary Diabetes Breakthrough: Gene-Edited Cell Technology Could End Daily Insulin Injections - StockTitan
Investors who lost money on Humacyte, Inc.(HUMA) should contact Levi & Korsinsky about pending Class ActionHUMA - ACCESS Newswire
HUMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
2 Firms Want To Co-Lead Humacyte Investor Suit - Law360
Humacyte, Inc. (HUMA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Humacyte: Upside Potential, But I Will Wait For Revenue Trends - Seeking Alpha
Cantor Fitzgerald Comments on Humacyte FY2025 Earnings - Defense World
Humacyte’s (HUMA) “Buy” Rating Reiterated at D. Boral Capital - Defense World
HUMACYTE ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Humacyte, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your RightsHUMA - ACCESS Newswire
Cantor Fitzgerald Estimates Humacyte FY2025 Earnings - MarketBeat
Humacyte moves to test bioengineered vessel in heart surgery - MSN
Humacyte moves to test bioengineered vessel in heart surgery By Investing.com - Investing.com Australia
DEADLINE ALERT for WOLF, HUMA, XRX, and ZETA: The Law - GlobeNewswire
DEADLINE ALERT for WOLF, HUMA, XRX, and ZETA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders - GlobeNewswire Inc.
Humacyte (NASDAQ:HUMA) Given Buy Rating at D. Boral Capital - MarketBeat
Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting - The Manila Times
Humacyte Announces Planned IND Filing in 2025 to Support - GlobeNewswire
Humacyte Sends First Shipment of Human Acellular Vessels to Ukraine as Part of Humanitarian Efforts - Fresenius Medical Care
11,105 Shares in Humacyte, Inc. (NASDAQ:HUMA) Acquired by Brookstone Capital Management - Defense World
Humacyte (NASDAQ:HUMA) Stock Price Up 10%Time to Buy? - MarketBeat
Cantor Fitzgerald Boosts Earnings Estimates for Humacyte - Defense World
Humacyte FY2024 EPS Forecast Raised by Cantor Fitzgerald - MarketBeat
Humacyte (NASDAQ:HUMA) Stock Price Down 6.4%What's Next? - MarketBeat
Class Action Filed Against Humacyte, Inc. (HUMA)January 17, 2 - GuruFocus.com
Faruqi & Faruqi Reminds Humacyte Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025HUMA - PR Newswire
HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
HUMA DEADLINE TODAY: ROSEN, A TOP RANKED LAW FIRM, - GlobeNewswire
HUMA DEADLINE TODAY: ROSEN, A TOP RANKED LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - GlobeNewswire Inc.
HUMA Deadline: Rosen Law Firm Urges Humacyte, Inc. (NASDAQ: HUMA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights - Business Wire
Faruqi & Faruqi Reminds Humacyte Investors of the Pending - GlobeNewswire
Cantor Fitzgerald Predicts Higher Earnings for Humacyte - MarketBeat
Levi & Korsinsky Notifies Humacyte, Inc. Investors of a Class Ac - GuruFocus.com
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte - Markets Insider
2025-01-16 | HUMA LAWSUIT ALERT: Levi & Korsinsky Notifies Humacyte, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline | NDAQ:HUMA | Press Release - Stockhouse Publishing
Humacyte, Inc. Class Action: Levi & Korsinsky Reminds Humacyte, - GuruFocus.com
Shareholders that lost money on Humacyte, Inc.(HUMA) should - GlobeNewswire
Humacyte, Inc. (NASDAQ:HUMA) Short Interest Update - MarketBeat
Humacyte, Inc. (HUMA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):